Le Lézard2d
New Five-Year Sotyktu (deucravacitinib) Data Show Consistent Safety and Durable Response Rates in Moderate-to-Severe Plaque Psoriasis
Bristol Myers Squibb today announced new five-year results from the POETYK PSO long-term extension (LTE) trial of Sotyktu (deucravacitinib) treatment in adult patients with moderate-to-severe plaque ...
GP magazine5d
Pictorial case study: Scalp folliculitis
Join MIMS now and pay nothing for the first 30 days Join GPOnline now and pay nothing for the first 30 days ...